ChemoCentryx to Participate in Two Upcoming Investor Conferences

Rhea-AI Summary

ChemoCentryx, Inc. (Nasdaq: CCXI) announced that CEO Thomas J. Schall will participate in two investor conferences in November 2021. The first event is the Stifel 2021 Virtual Healthcare Conference, featuring a fireside chat on November 17 at 2:00 p.m. ET. The second is the Piper Sandler 33rd Annual Virtual Healthcare Conference, with an on-demand presentation available from November 22 at 10:00 a.m. ET. Live webcasts and replays will be accessible on the company's website for two weeks post-event.

SAN CARLOS, Calif., Nov. 10, 2021 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that Thomas J. Schall, Ph.D., President and Chief Executive Officer, will participate in two upcoming investor conferences:

• Stifel 2021 Virtual Healthcare Conference
  Fireside Chat Wednesday, November 17 at 2:00 p.m. Eastern Time

• Piper Sandler 33rd Annual Virtual Healthcare Conference
  On-demand presentation available beginning Monday, November 22 at 10:00 a.m. Eastern Time
  

A live audio webcast of the Stifel fireside chat, as well as the on-demand Piper Sandler presentation can be accessed through the Investors section of the Company's website at www.ChemoCentryx.com. Replays of both the Stifel and Piper Sandler presentations will be available on the Company's website for two weeks following the respective presentation dates.

About ChemoCentryx
ChemoCentryx is a biopharmaceutical company commercializing and developing new medications for inflammatory and autoimmune diseases and cancer. ChemoCentryx targets the chemokine and chemoattractant systems to discover, develop and commercialize orally-administered therapies. In the United States, ChemoCentryx markets TAVNEOS™ (avacopan), the first approved orally-administered inhibitor of the complement 5a receptor as an adjunctive treatment for adult patients with severe active ANCA-associated vasculitis. TAVNEOS is also in late-stage clinical development for the treatment of severe Hidradenitis Suppurativa and C3 glomerulopathy (C3G). Additionally, ChemoCentryx has early-stage drug candidates that target chemoattractant receptors in other inflammatory and autoimmune diseases and in cancer. For more information visit www.chemocentryx.com

Contacts:

Susan M. Kanaya
Executive Vice President,
Chief Financial and Administrative Officer
investor@chemocentryx.com

Media:
Stephanie Tomei
408.234.1279
media@chemocentryx.com

Investors:
Lee Roth, Burns McClellan
212.213.0006
lroth@burnsmc.com

FAQ

When will ChemoCentryx CEO Thomas J. Schall speak at the Stifel 2021 Virtual Healthcare Conference?

Thomas J. Schall will participate in the Stifel 2021 Virtual Healthcare Conference on November 17, 2021, at 2:00 p.m. Eastern Time.

What is the schedule for the Piper Sandler 33rd Annual Virtual Healthcare Conference?

The Piper Sandler 33rd Annual Virtual Healthcare Conference will feature an on-demand presentation by Thomas J. Schall available beginning November 22, 2021, at 10:00 a.m. Eastern Time.

How can I access the live presentations from ChemoCentryx's investor conferences?

Live audio webcasts for both the Stifel and Piper Sandler presentations can be accessed through the Investors section of ChemoCentryx's website.

What is the focus of ChemoCentryx's business?

ChemoCentryx develops medications for inflammatory and autoimmune diseases and cancer, including TAVNEOS™, the first oral inhibitor of the complement 5a receptor.

Where can I find replays of the ChemoCentryx investor conference presentations?

Replays of the presentations will be available on ChemoCentryx's website for two weeks following the respective presentation dates.